NASDAQ:ONC Beigene (ONC) Stock Price, News & Analysis $268.45 +1.06 (+0.40%) As of 01:39 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsTrendsBuy This Stock About Beigene Stock (NASDAQ:ONC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Beigene alerts:Sign Up Key Stats Today's Range$264.43▼$275.2550-Day Range N/A52-Week Range$126.97▼$287.88Volume266,021 shsAverage Volume444,948 shsMarket Capitalization$26.48 billionP/E RatioN/ADividend YieldN/APrice Target$310.00Consensus RatingBuy Company OverviewBeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.Read More… Remove Ads Beigene Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks26th Percentile Overall ScoreONC MarketRank™: Beigene scored higher than 26% of companies evaluated by MarketBeat, and ranked 858th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.5 / 5Analyst RatingBuy Consensus RatingBeigene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBeigene has only been the subject of 3 research reports in the past 90 days.Read more about Beigene's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Beigene are expected to grow in the coming year, from ($5.82) to $0.71 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Beigene is -32.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Beigene is -32.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioBeigene has a PEG Ratio of 7.73. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioBeigene has a P/B Ratio of 7.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for ONC. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBeigene does not currently pay a dividend.Dividend GrowthBeigene does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for ONC. News and Social Media2.2 / 5News Sentiment0.89 News SentimentBeigene has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Beigene this week, compared to 7 articles on an average week.Search InterestOnly 1 people have searched for ONC on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat Follows6 people have added Beigene to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Beigene insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $270,454,249.00 in company stock.Percentage Held by InsidersOnly 7.43% of the stock of Beigene is held by insiders.Percentage Held by Institutions48.55% of the stock of Beigene is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Beigene's insider trading history. Receive ONC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Beigene and its competitors with MarketBeat's FREE daily newsletter. Email Address ONC Stock News HeadlinesBeigene, Ltd. (NASDAQ:ONC) Insider Sells $10,911,052.80 in StockMarch 21, 2025 | insidertrades.comBeigene, Ltd. (NASDAQ:ONC) Insider Sells $2,073,808.68 in StockMarch 7, 2025 | insidertrades.comWhile Markets Slide, These "Genesis Cog" Trades Are Up Double-DigitsWhile most investors are struggling in today's volatile market, a small group of traders are quietly booking consistent gains. Just last week, our Genesis Cog subscribers captured an 11.51% gain shorting JEF, another 8.57% on CAKE, and 4.78% on RJF—all while the broader indexes continued their downward trend.March 31, 2025 | Theo Trade (Ad)Beigene, Ltd. (NASDAQ:ONC) CEO John Oyler Sells 101,000 SharesMarch 6, 2025 | insidertrades.comBeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung CancerMarch 31 at 6:44 AM | finance.yahoo.comContrasting Beigene (ONC) & The CompetitionMarch 31 at 2:05 AM | americanbankingnews.comBank of America Securities Keeps Their Buy Rating on BeiGene (ONC)March 24, 2025 | markets.businessinsider.comBeiGene price target raised to $259 from $207 at BernsteinMarch 13, 2025 | markets.businessinsider.comSee More Headlines ONC Stock Analysis - Frequently Asked Questions How have ONC shares performed this year? Beigene's stock was trading at $223.50 at the beginning of the year. Since then, ONC shares have increased by 20.1% and is now trading at $268.45. View the best growth stocks for 2025 here. How were Beigene's earnings last quarter? Beigene, Ltd. (NASDAQ:ONC) issued its earnings results on Thursday, February, 27th. The company reported ($1.43) earnings per share for the quarter, missing analysts' consensus estimates of ($0.88) by $0.55. The business earned $1.13 billion during the quarter, compared to analysts' expectations of $1.09 billion. Beigene had a negative net margin of 25.94% and a negative trailing twelve-month return on equity of 25.12%. How do I buy shares of Beigene? Shares of ONC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings2/27/2025Today3/31/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ONC Previous SymbolNASDAQ:ONC CIK1651308 WebN/A Phone13459494123FaxN/AEmployees10,600Year FoundedN/APrice Target and Rating Average Stock Price Target$310.00 High Stock Price Target$348.00 Low Stock Price Target$259.00 Potential Upside/Downside+17.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($6.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth7.73Net Income$-881,710,000.00 Net Margins-25.94% Pretax Margin-24.07% Return on Equity-25.12% Return on Assets-14.95% Debt Debt-to-Equity Ratio0.05 Current Ratio1.93 Quick Ratio1.72 Sales & Book Value Annual Sales$3.81 billion Price / Sales6.86 Cash FlowN/A Price / Cash FlowN/A Book Value$37.10 per share Price / Book7.14Miscellaneous Outstanding Shares98,643,000Free Float90,588,000Market Cap$26.15 billion OptionableN/A Beta0.65 These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:ONC) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Great Society Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beigene, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Beigene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.